Antiretroviral treatment in correctional facilities

HIV Clinical Trials

Volumn 6, Issue 1, 2005, Pages 25-37

  Pontali, Emanuele ^a  

^a Prison of Genoa   (Italy)

Author keywords

Antiretroviral therapy; HIV; Prison

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; RIBAVIRIN; RIFAMPICIN; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ARTICLE; BONE MARROW DISEASE; COMORBIDITY; CONFIDENTIALITY; DIRECTLY OBSERVED THERAPY; DISEASE TRANSMISSION; DRUG SELF ADMINISTRATION; EXPERIENCE; FEASIBILITY STUDY; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEMATOLOGIC DISEASE; HEPATITIS; HEPATITIS VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ITALY; LABORATORY TEST; LIVER DYSFUNCTION; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MEDICAL SPECIALIST; MENTAL DISEASE; MYCOBACTERIUM TUBERCULOSIS; NEUROLOGIC DISEASE; PANCREATITIS; PATIENT CARE; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT PARTICIPATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRISON; TUBERCULOSIS;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; ITALY; PRISONERS; PRISONS;

EID: 17344366290     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/GTQM-QRM1-FDW8-Y2FT     Document Type: Article

References (58)

1. Hogg RS, Ealt KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;279:450-454.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860.
3. Hogg RS, Yip B, Kully C, et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ. 1999;160:659-665.
4. 3). HIV Clin Trials. 2000;1:9-16.
5. Lavalle C, Aguilar JC, Pena F, Estrada-Aguilar JL, Avina-Zubieta JA, Madrazo M. Reduction in hospitalization costs, morbidity, disability, and mortality in patients with AIDS treated with protease inhibitors. Arch Med Res. 2000;31:515-519.
6. Palepu A, Yip B, Miller C, et al. Factors associated with the response to antiretroviral therapy among HIV-infected patients with and without a history of injection drug use. AIDS. 2001;15:423-424.
7. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:81-87.
8. Moreno A, Perez-Elias MJ, Casado JL, et al. Long-term outcomes of protease inhibitor-based therapy in antiretroviral treatment-naive HIV-infected injection drug users on methadone maintenance programmes. AIDS. 2001;15:1068-1070.
9. Jensen-Fangel S, Pedersen L, Pedersen C, et al. The effect of race/ethnicity on the outcome of highly active antiretroviral therapy for human immunodeficiency virus type 1-infected patients. Clin Infect Dis. 2002;35:1541-1548.
10. Palepu A, Tyndall MW, Li K, et al. Alcohol use and incarceration adversely affect HIV-1 RNA suppression among injection drug users starting antiretroviral therapy. J Urban Health: Bull NY Acad Med. 2003;80(4):667-675.
11. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS. 2004;18(6):887-895.
12. Palombi L, Narciso P, Perno CF, et al. One year of HAART in Mozambique: survival, virological, and immunological results of DREAM project in adults and children. In: Program and abstracts of the XI Conference on Retroviruses and Opportunistic Infections; February, 8-11, 2004; San Francisco, California. Abstract 148.
13. UNAIDS. Prisons and AIDS: UNAIDS Point of View. Geneva, Switzerland: Author; 1997.
14. Repubblica Italiana. Ministero della Giustizia. Dipartimento dell'Amministrazione Penitenziaria. Indagine nazionale sui detenuti tossicodipendenti e affetti da virus HIV; rilevamento al 31/12/2001. Rome, Italy: Ministry of Justice; 2002.
15. Commissione nazionale per la lotta contro l'AIDS e le altre malattie infettive emergenti e riemergenti. L'infezione da HIV nell'ambito degli istituti penitenziari. Rome, Italy: Ministero della Salute; December 18, 2003.
16. Long J, Allwright S, Barry J, et al. Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in entrants to Irish prisons: a national cross sectional survey. BMJ. 2001;323:1-6.
17. Maruschak LM. Bureau of Justice Statistics Bulletin: HIV in Prisons and Jails, 1999. Document NCJ 187456, 2001. Available at: http://www.ojp.usdoj.gov/bjs/abstract/hivpj99.htm. Accessed September 20, 2004.
18. Maruschak LM. HIV in Prisons, 2001. Bureau of Justice Statistics, Bulletin. US Department of Justice, Office of Justice Programs; January 2004. Available at: http://www.ojp.usdoj.gov/bjs/abstract/hivp01.htm. Accessed September 20, 2004.
19. Guimaraes T, Granato CF, Varella D, Ferraz ML, Castelo A, Kallas EG. High prevalence of hepatitis C infection in a Brazilian prison: identification of risk factors for infection. Braz J Infect Dis. 2001;5(3):111-118.
20. Thaisri H, Lerwitworapong J, Vongsheree S, et al. HIV infection and risk factors among Bangkok prisoners, Thailand: a prospective cohort study. BMC Infect Dis. 2003;3:25.
21. WHO-EURO. HIV in Prisons. A Reader with Particular Relevance to the Newly Independent States. Copenhagen, Denmark: Author; 2001.
22. Hammett TM, Harmon MP, Rhodes W. The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997. Am J Public Health. 2002;92:1789-1794.
23. Hammet, TM. Public Health/Corrections Collaborations: Prevention and Treatment of HIV/AIDS, STDS, and TB. Washington, DC: National Institute of Justice; 1998.
24. Altice FL, Mostashari F, Friedland GH. Trust and the acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;28:47-58.
25. Dublin declaration on HIV/AIDS in prisons in Europe and Central Asia: Prison health is public health. Dublin, Ireland. February 23, 2004. Available at: http://www.euro.who.int/eprise/main/who/progs/HIPP/Home. Accessed August, 31 2004.
26. UNAIDS. Prisons and AIDS: UNAIDS Technical Update. Geneva, Switzerland: Author; 1997.
27. Spaulding A, Stephenson B, Macalino G, Ruby W, Clarke JG, Flanigan TP. Human immunodeficiency virus in correctional facilities: a review. Clin Infect Dis. 2002;35:305-312.
28. Mostashari F, Riley E, Selwyn PA, Altice FL. Acceptance and adherence with antiretroviral therapy among HIV-infected women in a correctional facility. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(4):341-348.
29. Baillargeon J, Borucki MJ, Zepeda S, Jenson HB, Leach CT. Antiretroviral prescribing patterns in the Texas prison system. Clin Infect Dis. 2000;31:1476-1481.
30. World Health Organization. Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Guidelines for a Public Health Approach, 2003 revision. Geneva, Switzerland: WHO; December 2003.
31. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents. March 23, 2004. Available at: http://www.aidsinfo.nih.gov//guidelines/adult/AA_032304.pdf. Accessed September 20, 2004.
32. Estelle v. Gamble, 429 US 97 (Supreme Court 1976); USA.
33. Judge says prison must obey NIH treatment guidelines. National Institute of Health. AIDS Policy Law. 1999;14(14):1-8.
34. Frank L. Prisons and public health: emerging issues in HIV treatment adherence. J Assoc Nurses AIDS Care. 1999;10(6):24-32.
35. Griffin MM, Ryan JG, Briscoe VS, Shadle KM. Effects of incarceration on HIV-infected individuals. J Natl Med Assoc. 1996;88:639-644.
36. Hubbard M., Piliero PJ, Moehs CJ, Battaglioli-DeNero A, eds. Nursing Care of the HIV-Infected Inmate Learning Module 3: Adherence & Resistance. Albany, NY: Albany Medical Center Hospital; 2003.
37. Gallego O, Corral A, de Mendoza C, González-Lahoz Juan, Soriano V. High rate of resistance to antiretroviral drugs among HIV-infected prison inmates. Med Sci Monit. 2003;9(6):CR269-273.
38. Samet JH, Libman H, Steger KA, et al. Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic. Am J Med. 1992;92:495-501.
39. Muma RD, Ross MW, Parcel GS, Pollard RB. Zidovudine adherence among individuals with HIV infection. AIDS Care. 1995;7:439-447.
40. O'Connor PG, Molde S, Henry S, Shockcor WT, Schottenfeld RS. Human immunodeficiency virus infection in injection drug users: a model for primary care. Am J Med. 1992;93:382-386.
41. Selwyn PA, Budner NS, Wasserman WC, Arno PS. Utilization of on-site primary care services by HIV-seropositive and seronegative drug users in a methadone maintenance program. Public Health Rep. 1993;108:492-500.
42. Solomon L, Vlahov D, Astemborski J, Galai N, Graham NMH, Nelson KE. Factors associated with initiation of zidovudine in a cohort of injection drug users. J Drug Issues. 1995;25:225-233.
43. Wohl DA, Stephenson BL, Golin CE, et al. Adherence to directly observed antiretroviral therapy among human immunodeficiency virus-infected prison inmates. Clin Infect Dis. 2003;36:1572-1576.
44. Babudieri S, D'Offizi GP, Carbonara S, Starnini G. Directly observed therapy to treat HIV infection in prisoners. JAMA. 2000;284(2):179-180.
45. Marco A, Cayla JA, Serra M, et al. Predictors of adherence to tuberculosis treatment in a supervised therapy programme for prisoners before and after release. Study Group of Adherence to Tuberculosis Treatment of Prisoners. Eur Respir J. 1998;12(4):967-971.
46. Wood E, Montaner JSG, Bangsberg DR, et al. Expanding access to HIV antiretroviral therapy among marginalized populations in the developed world. AIDS. 2003;17(17): 2419-2427.
47. White MC, Mehrotra A, Menendez E, Estes M, Goldenson J, Tulsky JP. Jail inmates and HIV care: provision of antiretroviral therapy and Pneumocystis carinii pneumonia prophylaxis. Int J STD AIDS. 2001;12(6):380-385.
48. Kim JY, Rich J, Zeiler S, et al. Successful community follow-up and reduced recidivism of HIV positive women prisoners. J Correctional Health Care. 1997;4:1-9.
49. Flanigan TP, Kim JY, Zierler S, Rich JD, Vigilante K, Bury-Maynard D. A prison release program for HIV-positive women: linking them to health services and community follow-up. Am J Public Health 1996;86:886-887.
50. Skolnick AA. Correctional and community health care collaborations. JAMA. 1998;279:98-99.
51. Wohl DA, Stephenson BL, Strauss R, et al. Access to HIV care and antiretroviral therapy following release from prison. In: Program and abstract of XI Conference on Retroviruses and Opportunistic Infections; February, 8-11, 2004; San Francisco, California. Abstract 859.
52. Howard TR, Campbell WA. Positive tools for HIV+ prisoners. In: Program and abstract of XV International AIDS Conference; July, 11-16, 2004; Bangkok, Thailand. Abstract number: WePeE6856.
53. Kennedy SS, Hammett TM, Braithwaite R, Arriola KRJ. Improving access to and utilization of health and social services for HIV-infected jail and prison releasees: evaluation results from the Corrections Demonstration Project funded by the Centers For Disease Control and Prevention (CDC) and Health Resources and Services Administration (HRSA). In: Program and abstract of XV International AIDS Conference; July, 11-16, 2004; Bangkok, Thailand. Abstract ThPeE7996.
54. Babudieri S, Starnini G, Brunetti B, et al. HIV e infezioni correlate negli Istituti Penitenziari Italiani: note di epidemiologia e di organizzazione sanitaria. Ann Ist Super Sanità. 2003;39(2):251-257.
55. García-Guerrero J, Herrero A, Bedia M, Araújo R, Castellano JC. Grupo de Estudio REPRICOVA. Resistencias primarias de VIH en una población penitenciaria. Estudio REPRICOVA-2. Enferm Infecc Microbiol Clin. 2004;22:29-31.
56. Kirkland LR, Fischl MA, Tashima KT, et al. for the NZTA4007 Study Team. Response to Lamivudine-Zidovudine plus Abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment. Clin Infect Dis. 2002;34:511-518.
57. Europe Council. Recommandation N.R. (93) 6 du Comité des Ministres aux Etats membres concernant les aspects pénitentiaires et criminologiques du contrôle des maladies transmissible et notamment du SIDA, et les problèmes connexes de santé en prison. 1993.
58. Palmiere C, Toscanini F. La normativa italiana in materia di AIDS. Istituto Italiano di Medicina Sociale. Rome, Italy; 2004.